Brainomix has unveiled a new collaboration with French medical neurology imaging company Pixyl to expand its offering with the latter’s multiple sclerosis (MS) treatment.

Under the partnership deal, the company will be responsible for distributing Pixyl’s software-as-a-Service (SaaS) solution, Neuro.MS.

The Neuro.MS SaaS solution has been designed for the diagnosis and treatment of MS patients.

It leverages advanced deep-learning technology to provide clinicians and radiologists with clinically relevant information regarding neurological disorders such as MS.

The solution automatically analyses MRI images of the brain to identify, quantify and track abnormalities within five minutes.

It offers access to quantified and classified white matter hyperintensities along with quantified measures of lesion volumes and brain atrophy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Brainomix co-founder and CEO Dr Michalis Papadakis said: “We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions.

“We recognised that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions.

“We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”

The company will distribute Pixyl’s SaaS solution exclusively in Ireland, the US, the Nordics, and important markets across Eastern Europe.

A CE mark-approved Class IIA product, the Neuro.MS solution will be offered to the company’s existing customer base alongside its e-Stroke platform, a comprehensive stroke imaging solution.